Implementing prognostic and predictive biomarkers in CRC clinical trials.
about
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewPersonalized treatment for advanced colorectal cancer: KRAS and beyondIdentification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new eraUDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerCancer research: from prognostic genes to therapeutic targetsA rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources.Strategies for power calculations in predictive biomarker studies in survival dataMolecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic studyA 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer.Lung cancer transcriptomes refined with laser capture microdissection.The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer.KRAS mutation testing in metastatic colorectal cancerCT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.Systems vaccinology: its promise and challenge for HIV vaccine development.An update on miRNAs as biological and clinical determinants in colorectal cancer: a bench-to-bedside approach.Endoplasmic reticulum ribosome-binding protein 1, RRBP1, promotes progression of colorectal cancer and predicts an unfavourable prognosis.Primary tumor location as a prognostic factor in metastatic colorectal cancer.Evidence for possible non-canonical pathway(s) driven early-onset colorectal cancer in India.ColoFinder: a prognostic 9-gene signature improves prognosis for 871 stage II and III colorectal cancer patients.Colorectal cancer cells are resistant to anti-EGFR monoclonal antibody through adapted autophagy.Ginsenoside Rh2 alleviates tumor-associated depression in a mouse model of colorectal carcinomaFiltered selection coupled with support vector machines generate a functionally relevant prediction model for colorectal cancer.Translating clinical research of Molecular Biology into a personalized, multidisciplinary approach of colorectal cancer patientsCo-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.Anti-EGFR antibody sensitizes colorectal cancer stem-like cells to Fluorouracil-induced apoptosis by affecting autophagy.Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Individualization of cancer treatment from radiotherapy perspective.MicroRNAs: relevant tools for a colorectal surgeon?Proteomics, genomics and transcriptomics: their emerging roles in the discovery and validation of colorectal cancer biomarkers.Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.MiR-497 promotes metastasis of colorectal cancer cells through Nrdp1 inhibition.Role of Lgr5-positive cells in colorectal cancer.Astrocyte elevated gene-1 activates MMP9 to increase invasiveness of colorectal cancer.Novel markers for circulating tumor stem cells in colorectal carcinomaThe role of Nrf2-Keap1 axis in colorectal cancer, progression, and chemoresistance.The role of microRNAs in colorectal liver metastasis: Important participants and potential clinical significances.Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy.Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
P2860
Q26766584-573F9F99-ECF5-46F1-A4F7-1E39EE514E6FQ26822817-89FA46A4-3643-454D-8424-8DE316D6B041Q27693248-4E225FCD-3D09-421B-B9B0-15A0A4F76A57Q27853065-6937B7E4-1BC4-49B3-8B62-32A4DDF1791CQ28084216-A5D2A80F-F4A9-4576-82DD-F908813FA979Q28396195-EBB52702-8CA3-4620-AEA2-6B9E2EA667A8Q31056926-44BA6DFC-68E4-437E-99F0-3C160357349CQ31132692-97D8EB4A-B75E-4747-8E5D-39F608501DDBQ33682949-F148F19C-6539-4435-9D5E-A50E5B7BE429Q34227755-23658233-4BA7-46BD-8E6F-4FFD90AC3EECQ34429985-54E8EFE6-0A4E-4271-AB2A-2CD0637B8239Q34441849-67AB8A37-95FB-423B-A692-731A2CB7F267Q34643960-C702D928-F1F4-4172-AB92-951A2FE526C7Q34998534-2C129D7B-D1D3-4660-9CC9-B412BACA8A2DQ35510634-7BD16D73-C883-49E4-B0F9-DB936CCFAC19Q35659539-FDAE85A1-6AE2-4262-96C4-EC4D71D88510Q35811250-F7363F2B-890F-4777-8AC2-BC03558CF591Q36027048-A6A7E776-427D-496A-8327-EE84255E740EQ36047405-1900F1FA-69E6-4495-AC6C-941619FEB645Q36685016-A0D69AFC-A7A1-4566-BD9E-B7BB476AA862Q36691267-9EAA228C-AD43-4C4D-BAF1-F3251F156C90Q36841375-06B313F1-8CA3-4232-A87B-9C25CCE56B79Q36964127-9E6928F3-1224-43DA-BCCB-A4031B13D887Q36982254-F67F1E55-DBC0-450F-B0E1-5F173C0555A9Q37640727-F7FDE48D-2A4A-482F-A5E1-8258D13AD186Q37697137-609D0DA0-D046-4946-84CF-86573F45050CQ37697172-9E312609-2040-43C3-8BA5-CBB5C8E18BFBQ37731264-42891961-927D-4A5C-B4AC-9B6637B37076Q37989616-6085334D-355E-4612-BA89-18DDD09E6141Q38004774-167285AB-E54A-4AAF-A49B-AB95BD641DCBQ38194582-C768AF4C-FD77-4CAD-BDDC-AF20790B8AB6Q38856729-00EB90D1-C52B-4560-A2E0-E429BCD269BBQ38880709-2AB37ED0-467D-46C3-A7C6-B8713C53C4ADQ38891622-B5DDF994-CD4D-404C-B5C2-6F3BF2C716C5Q39007262-344527F6-6857-4ED8-9FDF-ED11B3C4E137Q39200398-15CF293C-4556-4681-BA12-7CFBA197A74AQ39377881-135E98F5-748F-445B-AAD4-C8334DE05707Q39398929-195C2D01-100A-4B27-9442-0F12D465C539Q39590420-67D4CB17-61B7-41F5-BE5B-2088340DABE3Q40198390-9C7634C8-0B2C-44F5-B0B9-9BAD3BB2117C
P2860
Implementing prognostic and predictive biomarkers in CRC clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Implementing prognostic and predictive biomarkers in CRC clinical trials.
@en
Implementing prognostic and predictive biomarkers in CRC clinical trials.
@nl
type
label
Implementing prognostic and predictive biomarkers in CRC clinical trials.
@en
Implementing prognostic and predictive biomarkers in CRC clinical trials.
@nl
prefLabel
Implementing prognostic and predictive biomarkers in CRC clinical trials.
@en
Implementing prognostic and predictive biomarkers in CRC clinical trials.
@nl
P2093
P2860
P1476
Implementing prognostic and predictive biomarkers in CRC clinical trials.
@en
P2093
Patrick G Johnston
Richard C Turkington
Sandra Van Schaeybroeck
Wendy L Allen
P2860
P304
P356
10.1038/NRCLINONC.2011.15
P407
P577
2011-02-15T00:00:00Z